Sarah Whelan

1.2k total citations
25 papers, 681 citations indexed

About

Sarah Whelan is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sarah Whelan has authored 25 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sarah Whelan's work include CAR-T cell therapy research (8 papers), Immune Cell Function and Interaction (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Sarah Whelan is often cited by papers focused on CAR-T cell therapy research (8 papers), Immune Cell Function and Interaction (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Sarah Whelan collaborates with scholars based in United Kingdom, United States and Ireland. Sarah Whelan's co-authors include Cliona O’Farrelly, Cathal Harmon, J Ferlay, Justin Geoghegan, Diarmaid D. Houlihan, Mark W. Robinson, Maya F. Kotturi, Eran Ophir, Drew M. Pardoll and Sudipto Ganguly and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Sarah Whelan

23 papers receiving 667 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Whelan United Kingdom 11 335 288 127 107 69 25 681
JR Gralow United States 9 415 1.2× 369 1.3× 230 1.8× 128 1.2× 73 1.1× 34 796
Davor Frleta United States 12 491 1.5× 227 0.8× 234 1.8× 86 0.8× 59 0.9× 18 847
Manuel Schmidt Germany 14 603 1.8× 353 1.2× 273 2.1× 59 0.6× 40 0.6× 50 1.0k
Farhad Ghasemi Canada 15 202 0.6× 208 0.7× 201 1.6× 138 1.3× 46 0.7× 29 584
Matthew M. Seavey United States 15 359 1.1× 255 0.9× 219 1.7× 34 0.3× 114 1.7× 21 818
Lorenzo Uccellini United States 14 278 0.8× 315 1.1× 143 1.1× 58 0.5× 53 0.8× 20 526
Yu Yu United States 15 450 1.3× 118 0.4× 163 1.3× 53 0.5× 39 0.6× 24 685
Annacarmen Petrizzo Italy 18 556 1.7× 439 1.5× 354 2.8× 95 0.9× 59 0.9× 30 922
Wandi Zhang United States 10 255 0.8× 204 0.7× 177 1.4× 44 0.4× 31 0.4× 26 668
Hans‐Peter Dienes Germany 12 260 0.8× 160 0.6× 202 1.6× 76 0.7× 52 0.8× 18 696

Countries citing papers authored by Sarah Whelan

Since Specialization
Citations

This map shows the geographic impact of Sarah Whelan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Whelan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Whelan more than expected).

Fields of papers citing papers by Sarah Whelan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Whelan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Whelan. The network helps show where Sarah Whelan may publish in the future.

Co-authorship network of co-authors of Sarah Whelan

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Whelan. A scholar is included among the top collaborators of Sarah Whelan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Whelan. Sarah Whelan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kivitz, Alan, Melvin Churchill, Atul Singhal, et al.. (2024). Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study. Arthritis & Rheumatology. 77(2). 171–179. 1 indexed citations
3.
Collins, Graham P., William Townsend, Swathi Namburi, et al.. (2023). A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL. Blood. 142(Supplement 1). 3093–3093. 3 indexed citations
4.
5.
Sharp, Adam, Sarah P. Blagden, Elizabeth Ruth Plummer, et al.. (2022). A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.. Journal of Clinical Oncology. 40(16_suppl). TPS2691–TPS2691. 8 indexed citations
6.
Sharp, Adam, Sarah P. Blagden, Daniel Hochhauser, et al.. (2022). PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL. HemaSphere. 6. 1970–1971. 3 indexed citations
7.
Whelan, Sarah, Jennifa Gosling, Frederick Cohen, et al.. (2021). 98 NX-0255, a small molecule CBL-B inhibitor, expands and enhances tumor infiltrating lymphocytes (TIL) for use in adoptive cancer immunotherapy. Regular and Young Investigator Award Abstracts. A107–A107. 4 indexed citations
8.
Hansen, Kyle, Sandeep Kumar, Kathryn Logronio, et al.. (2021). COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunology Immunotherapy. 70(12). 3525–3540. 29 indexed citations
9.
Alteber, Zoya, Maya F. Kotturi, Sarah Whelan, et al.. (2021). Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis. Cancer Discovery. 11(5). 1040–1051. 37 indexed citations
10.
Li, Jessica, Sarah Whelan, Maya F. Kotturi, et al.. (2020). PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia. Haematologica. 106(12). 3115–3124. 23 indexed citations
11.
Whelan, Sarah, Eran Ophir, Maya F. Kotturi, et al.. (2019). PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function. Cancer Immunology Research. 7(2). 257–268. 125 indexed citations
12.
13.
Coughlan, Alice M., Cathal Harmon, Sarah Whelan, et al.. (2016). Myeloid Engraftment in Humanized Mice: Impact of Granulocyte-Colony Stimulating Factor Treatment and Transgenic Mouse Strain. Stem Cells and Development. 25(7). 530–541. 95 indexed citations
14.
Harmon, Cathal, Mark W. Robinson, Sarah Whelan, et al.. (2016). Tissue‐resident Eomeshi T‐betlo CD56bright NK cells with reduced proinflammatory potential are enriched in the adult human liver. European Journal of Immunology. 46(9). 2111–2120. 112 indexed citations
15.
Coughlan, Alice M., Cathal Harmon, Sarah Whelan, et al.. (2016). Myeloid engraftment in humanized mice: impact of GCSF treatment and transgenic mouse strain. 1 indexed citations
16.
Bertelli, Gianfilippo, Ian M. Humphreys, William J. Valentine, et al.. (2013). A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK. British Journal of Cancer. 108(11). 2250–2258. 77 indexed citations
17.
18.
Holt, S, Gianfilippo Bertelli, Elaine Brinkworth, et al.. (2011). P5-14-26: Results from a Prospective Clinical Study on the Impact of Oncotype DX on Adjuvant Treatment Decision Making in a Cohort of 142 UK Patients.. Cancer Research. 71(24_Supplement). P5–14. 6 indexed citations
19.
Yang, Ling, et al.. (2005). Statistics on cancer in China: cancer registration in 2002. European Journal of Cancer Prevention. 14(4). 329–335. 39 indexed citations
20.
Sankaranarayanan, R, et al.. (1996). Cancer in Gabon, 1984-1993: a pathology registry based relative frequency study.. PubMed. 83(9). 693–6. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by JR Gralow Breakdown of academic impact, for papers by Davor Frleta Breakdown of academic impact, for papers by Manuel Schmidt Breakdown of academic impact, for papers by Farhad Ghasemi Breakdown of academic impact, for papers by Matthew M. Seavey Breakdown of academic impact, for papers by Lorenzo Uccellini Breakdown of academic impact, for papers by Yu Yu Breakdown of academic impact, for papers by Annacarmen Petrizzo Breakdown of academic impact, for papers by Wandi Zhang Breakdown of academic impact, for papers by Hans‐Peter Dienes
Rankless by CCL
2026